measure of inflammation being part of routine clinical care at minimal cost and inconvenience to the patient. It is hypothesised that raised Neutrophil Lymphocyte Ratio (NLR) and Platelet Lymphocyte Ratio (PLR) are two such markers associated with poor prognosis in ovarian cancer. Hence, this study was conducted to find association NLR and PLR with survival outcome in ovarian cancer.

Methods This study was conducted in a tertiary care teaching hospital after ethical clearance from Institutional ethics committee and written informed consent from all patients recruited. Records of 260 ovarian cancer cases admitted over five years were retrospectively searched for pretreatment neutrophil, lymphocyte and platelet counts to calculate NLR and PLR. Details of demography, disease characteristics, treatment and recurrence were recorded. Survival outcomes were correlated with the NLR and PLR. Statistical analysis was performed on SPSS version 21 using ROC curves and correlation analysis.

Results NLR and PLR had negative correlation with 5-year overall survival rate. ROC analysis showed that NLR below 2.8 was associated with 5 year OS of 72.2% while NLR above 2.8 was associated with OS of 27.8%. PLR below 204 was associated with 5 year OS of 77.7% while that above 204 was associated with 5 year OS of 22.3%.

Conclusion/Implications Both Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio are independent prognostic inflammatory markers for survival of ovarian cancer.

EP306/#96 IMPACT OF OBESITY ON TREATMENT AND SURVIVAL OUTCOME IN EPITHELIAL OVARIAN CANCER PATIENT: A 10-YEAR RETROSPECTIVE STUDY

Asavarak Sompohnmanas*, Vuthinun Achariyapota. Siriraj Hospital, Mahidol University, Obstetrics and Gynecology, Bangkok, Thailand

Introduction To evaluate the impact of obesity on surgical outcomes, adverse effects of chemotherapy, and survival outcomes among patients with epithelial ovarian cancer in the Thai population.

Methods We retrospectively reviewed the medical records of epithelial ovarian cancer patients who underwent staging laparotomy at Siriraj Hospital from January 2008 to December 2018. Patient characteristics, surgical outcomes, chemotherapy-related complications, and survival were compared between non-obese (BMI < 25.0) and obese (BMI ≥ 25) patients using the Western Pacific Regional Office (WPRO) BMI cut-off criteria.

Results Of the 444 patients initially included, 18 were excluded, leaving 426 patients for analysis, with 21.9% (n=93) in the obesity group and 78.1% (n=333) in the non-obesity group. The obesity group had a higher incidence of diabetes mellitus (P < 0.0001), hypertension (P = 0.003), and dyslipidemia (P = 0.027) than the non-obesity group. Obesity was independently associated with postoperative complications, including wound problems (adjusted OR: 6.175; 95% CI: 1.891–13.191; P < 0.001) and venous thromboembolism (adjusted OR: 5.991; 95% CI: 2.848–12.605; P < 0.001), but fewer event of neutropenia (P = 0.002) and delays in chemotherapy administration (P = 0.015). The two groups had no significant difference in progression-free survival (P = 0.133) or five-year overall survival (P = 0.923).

Conclusion/Implications Obesity does not affect survival outcomes in patients with epithelial ovarian cancer but increases the risk of postoperative complications, including wound complications and venous thromboembolism.